| http://www.w3.org/ns/prov#value | - This agreement emphasizes the potential value of our MedPulser(R) DNA Delivery System to facilitate the use of DNA vaccines to treat numerous diseases, including HIV and cancer, said Avtar Dhillon, MD, Genetronics' president and CEO. Vical conducted pre-clinical studies using our electroporation technology, and their decision to establish this agreement is another validation of the instrumental
|
